- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Alpha Tau Medical Ltd.: Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer | 37 | GlobeNewswire (Europe) | JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT- , today announced that the FDA... ► Artikel lesen | |
| Di | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.11. | Alpha Tau Medical GAAP EPS of -$0.39 | 1 | Seeking Alpha | ||
| 20.11. | Alpha Tau Medical Ltd.: Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update | 1.309 | GlobeNewswire (Europe) | - Alpha DaRT pancreatic cancer patient treatments underway in U.S. multi-center pilot study - - Newly received radioactive material license for New Hampshire facility positions the Company for continued... ► Artikel lesen | |
| 20.11. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| ALPHA TAU MEDICAL Aktie jetzt für 0€ handeln | |||||
| 23.10. | Alpha Tau Medical stock holds Buy rating at H.C. Wainwright after license win | 1 | Investing.com | ||
| 21.10. | Alpha Tau Medical Ltd.: Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness | 2 | GlobeNewswire (USA) | ||
| 21.10. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.09. | Alpha Tau Medical Ltd.: Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial | 3 | GlobeNewswire (USA) | ||
| 27.08. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 11.08. | Alpha Tau Medical Ltd.: Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update | 300 | GlobeNewswire (Europe) | - FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical... ► Artikel lesen | |
| 23.06. | Alpha Tau files to sell 3.46M ordinary shares by selling shareholders | 3 | Seeking Alpha | ||
| 17.06. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.05. | Alpha Tau Medical Ltd.: Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update | 345 | GlobeNewswire (Europe) | - Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive... ► Artikel lesen | |
| 28.04. | Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical | 629 | PR Newswire | Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology
Accelerating multiple late-stage cancer therapies... ► Artikel lesen | |
| 02.04. | Alpha Tau Medical Ltd.: Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma | 310 | GlobeNewswire (Europe) | JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA... ► Artikel lesen | |
| 12.03. | Alpha Tau Medical Ltd.: Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update | 886 | GlobeNewswire (Europe) | - Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 46,860 | +1,06 % | Fresenius Kabi Expands Simplist Portfolio of Prefilled Syringes | ||
| FRESENIUS MEDICAL CARE | 40,900 | +0,47 % | Neue 3,250%-Anleihe von Fresenius Medical Care | Stuttgart (www.anleihencheck.de) - Fresenius Medical Care (ISIN DE0005785802/ WKN 578580) hat eine Unternehmensanleihe (ISIN XS3233499089/ WKN A460DH) mit einem Volumen von bis zu 500 Millionen Euro... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 35,140 | 0,00 % | BMO Capital Maintains Bullish 12%+ BrightSpring EBITDA Growth Outlook on Drug Contract Wins, Generic Conversions | ||
| ALIGNMENT HEALTHCARE | 19,090 | +0,05 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 42,520 | -0,16 % | EQS-DD: Siemens Healthineers AG: Elisabeth Staudinger-Leibrecht, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
28.11.2025 / 17:23... ► Artikel lesen | |
| GENEDX | 160,60 | -1,84 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 29,530 | -2,86 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,000 | -0,25 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| PROGYNY | 24,950 | -1,27 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| GERRESHEIMER | 25,620 | -4,12 % | INDEX-MONITOR: JPMorgan erwartet Aumovio im MDax - Dax wohl unverändert | FRANKFURT (dpa-AFX) - Im Dax dürfte zur Index-Überprüfung an diesem Mittwoch alles beim Alten bleiben. Eine Änderung erwartet die US-Bank JPMorgan dagegen im Index der mittelgroßen Unternehmen, die... ► Artikel lesen | |
| BETA BIONICS | 28,440 | -3,50 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 42,940 | -0,88 % | EQS-AFR: Carl Zeiss Meditec AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Carl Zeiss Meditec AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Carl Zeiss Meditec AG: Vorabbekanntmachung... ► Artikel lesen | |
| ADAPTHEALTH | 9,430 | 0,00 % | AdaptHealth: Strategische Expansion und Technologie-Investitionen als Wachstumstreiber | ||
| PACS GROUP | 31,460 | 0,00 % | PACS Group, Inc. - 8-K, Current Report | ||
| NEUROPACE | 16,020 | +2,50 % | NeuroPace, Inc.: NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases | MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued... ► Artikel lesen |
Das Unternehmen ALPHA TAU MEDICAL LTD kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 3,870 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TAU MEDICAL LTD finden Sie auf Wallstreet Online.